Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Okayama University research: Peptide directs artificial tissue growth
  • USA - English


News provided by

Okayama University

Aug 05, 2015, 00:00 ET

Share this article

Share toX

Share this article

Share toX

a) Schematic illustration of the RGD-modified hydrogel (left) and the submandibular gland (SMG) tissue culture on hydrogel (right)
a) Schematic illustration of the RGD-modified hydrogel (left) and the submandibular gland (SMG) tissue culture on hydrogel (right)

Okayama, Japan (PRWEB UK) 5 August 2015 -- Studies on peptide-modified cultures reported in Scientific Reports demonstrate control over both tissue growth and location in vitro. These results can have a variety of uses including producing tissue arrays for drug screening and as a biologic tool to understand tissue development.

This in vitro SMG tissue growth modulation system can have a variety of uses including tissue arrays for drug screening and as a biologic tool to understand tissue development.

Post this

“In vitro fabricated biological tissue would be a valuable tool to screen newly synthesized drugs or understand the tissue development process,” explain Takuya Matsumoto and his colleagues in a recent report. However tissues grown so far have not reached the size and final shape of natural tissue. Matsumoto and colleagues at Okayama, Osaka and Kansai Universities in Japan have now identified a tripeptide sequence that can be used to overcome both limitations. With hydrogel modified with the tripeptide they demonstrate enhanced tissue growth of a salivary gland both across a sheet of tissue and at specified localised points.

The salivary gland studied - the submandibular gland - develops a branched structure through budding and the elongation of ducts, which is also typical of other structures such as lungs, kidneys, mammary glands and spleen. Previous research revealed the importance of the glycoprotein fibronectin in the morphological development and growth of salivary gland tissue. Consequently Matsumoto and colleagues focused their investigations on the effects of the specific tripeptide sequence arginine-glycine aspartic acid (RGD) that acts as a cell binding site on fibronectin.

The researchers studied the growth of salivary gland tissue on hydrogel both modified with different concentrations of RGD and without and found significant growth enhancements that increased with RGD concentrations. They then experimented with RGD-modified hydrogel beads and demonstrated that localised growth enhancement occurred where the beads were situated, which could provide control over morphology in artificial tissue growth. Further studies also suggested that neuronal growth and the enhancement of growth factor proteins were responsible for the enhanced gland tissue growth observed.

In their report of the work the researchers conclude, “This in vitro SMG tissue growth modulation system can have a variety of uses including tissue arrays for drug screening and as a biologic tool to understand tissue development.”

Background
Tripeptide in previous studies
The shape development or morphogenesis of the submandibular gland develops through the formation of clefts that occur through a change in cell adhesion so that they bind to the surrounding extracellular matrix instead of each other. Previous research has shown that expression of the glycoprotein fibronectin is crucial for cleft formation.

Integrin is a receptor protein that bridges interactions between cells and the extracellular matrix. The domain of fibronectin that binds to integrin is the tripeptide sequence arginine-glycine aspartic acid (RGD) prompting studies of this tripeptide sequence on tissue growth.

Investigations have already shown that transplanting composites containing RGD peptides onto the back of a mouse can result in the development of growth plates – the tissue at the ends of bones in growing children and adolescents. However so far there have been no studies into the growth and morphology of tissues in vitro. The ability to grow tissues in vitro is particularly important for drug screening and studies to better understand tissue growth.

The role of FGFs
Fibroblast growth factors (FGFs) are a family of proteins involved in embryonic development, wound healing and signalling pathways. Two specific FGFs play a crucial role in the growth of the two main tissue types in the submandible salivary gland – FGF7 induces budding in the epithelial tissue and FGF10 induces the elongation of ducts in the mesenchymal tissue.

Matsumoto and colleagues imaged the salivary gland tissues grown in RGD-modified hydrogels using immunofluorescent staining and found both FGF7 and FGF10 were highly expressed. Experiments to grow the salivary gland tissues in the presence of FGF7 and FGF10 antibodies revealed that these antibodies inhibited tissue growth. The RGD-modified hydrogel was also ineffective at enhancing tissue budding in isolated epithelial cells alone.

The role of neurites
Previous studies have also suggested that neuron outgrowths – ‘neurites’ – from a region known as the parasympathetic ganglion in submandibular gland tissue are key to tissue growth. The researchers observed an even distribution of the neurite network throughout the gland tissues they had grown. Antibodies to the neurotrophic factors, which are responsible for neuron growth and survival, also inhibited submandibular gland tissue growth in RGD-modified hydrogels.

Reference
Authors: Hiroaki Taketa, Gulsan Ara Sathi, Mahmoud Farahat, Kazi Anisur Rahman, Takayoshi Sakai, Yoshiaki Hirano, Takuo Kuboki, Yasuhiro Torii, Takuya Matsumoto.
Title: Peptide-modified Substrate for Modulating Gland Tissue Growth and Morphology In Vitro.
Journal: Scientific Reports 5, Article number: 11468 (2015).
DOI: 10.1038/srep11468
http://www.nature.com/articles/srep11468

Correspondence to
Professor Takuya Matsumoto, D.D.S., Ph.D.
Department of Biomaterials, Okayama University, 2-5-1 Shikata-Cho, Okayama, 700-8558, Japan.

<Archive of Okayama University Research Updates>
Vol.12:Molecular features of the circadian clock system in fruit flies
http://www.okayama-u.ac.jp/en/tp/release/release_id315.html
Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Planning and Public Information Division, Okayama University
E-mail: http://www.adm(at)adm(dot)okayama-u(dot)ac(dot)jp
Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

About Okayama University
Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Education House sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 14,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences. Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

https://www.youtube.com/watch?v=iDL1coqPRYI

Ms Shiho Kinoshita, Okayama University, +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.